medicine
Medicine
The Innovative Technologies Research Institute was established to develop high-end generics and reformulated medicines. Over the years, we have built strong IP portfolio and core technologies that are highly competitive in this field world-wide. Our comprehensive toolkit consists of 7 DSS and API platforms – liposomes, inhalation formulations, polymeric microspheres, emulsions, solid dosage forms, liquid dosage forms, and API synthesis & scale-up. Leveraging these, we strive to develop innovative, differentiated medicines that deliver hope and better life quality to patients.
| Pipeline | SN | Product Number | Product Introduction |
|---|---|---|---|
| Oncology | 1 |
JMX-2002
|
Class 2.2 innovative liposomes are intended for conventional chemotherapy of multiple tumors, including non-small cell lung cancer, and can significantly reduce the toxicity issues caused by chemotherapy drugs. |
| 2 |
JM045
|
2.2 class long-acting microspheres for chemical drugs, used for endocrine therapy of sex hormone related tumors | |
| 3 |
JMX-2006
|
2.2 class long-acting microspheres for chemical drugs, used for endocrine therapy of sex hormone related tumors | |
| Cardiovascular Diseases | 4 |
JMX-2005
|
Class 2.2 innovative liposomes for chemical drugs, used in vascular diseases to meet clinical needs |
| Respiratory Diseases | 5 |
JMX-2007
|
2.2+2.4 inhalation formulations of chemical drugs, with no competition in the same variety both domestically and internationally |
| 6 |
JMX-2101
|
Class 2.2 inhalation preparations for chemical drugs, with high medication convenience | |
| 7 |
JMZ-2201
|
Improved traditional Chinese medicine, inhalation dosage form, good safety, convenient for children's treatment | |
| 8 |
JMX-2201
|
Tripartite inhaled aerosols are expected to become iterative treatment products | |
| Pain | 9 |
JM023
|
2.2 class long-acting microspheres for chemical drugs, meeting the clinical pain treatment needs |
| 10 |
JMX-2102
|
Class 2.2 long-acting microsphere compound formulation for chemical medicine, meeting the clinical pain treatment needs |
The Innovative Technologies Research Institute is led by seasoned leadership team with more than 20 years scientific and management experiences from leading pharmaceutical companies around the world. Currently, the institute has about 200 scientists and more than 60% of them hold MS and PhD degrees.
Compound liposome technology
Weak base/acid drug liposome system
Modified targeted liposomes
Liposome-device integration and other technologies
Dry powder inhalers
Metered dose inhaler
Nasal spray
Other mucosal drug delivery formulations
Single emulsion platform
Complex emulsion platform
Phase separation platform
Suspension technology
Long-acting gels
Focused TCM development: categories 1.1 and 1.2
Expanded TCM pipelines: nephropathy, respiratory diseases, pain, and cardiovascular diseases
Developing next-generation TCM products: identification of active components, development of novel TCM entities, IND filing, clinical developemnt, NDA filing
Advancing TCM series: reproduction of traditional products, optimization of process development, improvement of quality, exploration of clinical value
API manufacturing (formulation platforms / API registration): liposomes, inhalation formulations, microspheres, solid dosage forms, liquid dosage forms
Developing novel chemical technologies and green processes: chiral syntheses and telescoping syntheses, high performance membrane and resin separation, impurities separation and syntheses, quality control, polymorph study
Product supporting: marketed and license-in products of Jemincare Group
Immediate release formulations (rapid onset of action)
Solubility-improving technologies for insoluble molecules
Sustained release formulations (daily administration)
Multi-unit formulation for extended and controlled release
High-end oral liquid preparations: oral emulsion, oral suspension, oral phospholipid dispersion, and enteral nutrition emulsion
Special injectables: lipid injectable emulsions, plasma substitute, injectable suspension
Nanchang National High-tech Industrial
Development Zone, Jiangxi Province,
China No. 3333, West Yaohu Avenue
Tel:0791-87339727
Fex:0791-87339712
Email:service@hxf5566.com(PR)
